Same-day Strattera appointment in Pennsylvania

If you’re managing ADHD and wondering whether you can access non-stimulant medications like Strattera through telehealth, you’re not alone. Millions of Americans now turn to virtual care for mental health treatment, and ADHD management has become one of the most sought-after telehealth services. The short answer is yes—in most cases, you can receive ADHD non-stimulant medications via telehealth without ever stepping into a doctor’s office.

But navigating the world of online ADHD care can feel overwhelming. Federal and state laws are constantly evolving, provider credentials vary, and misinformation abounds. This guide will walk you through everything you need to know about accessing ADHD non-stimulant medications through telehealth in 2025, including current regulations, state-by-state differences, and what to expect from your virtual appointments.

Understanding ADHD Non-Stimulant Medications

Before diving into telehealth logistics, it’s important to understand what non-stimulant ADHD medications are and how they differ from their stimulant counterparts.

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications treat ADHD through different mechanisms than traditional stimulants like Adderall or Ritalin. The most commonly prescribed non-stimulant is Strattera (atomoxetine), which works by selectively inhibiting the reuptake of norepinephrine in the brain. Unlike stimulants that provide immediate symptom relief, Strattera typically takes 4–6 weeks to reach full effectiveness.

Other non-stimulant options include:

• Intuniv (guanfacine)
• Kapvay (clonidine)
• Qelbree (viloxazine)

The Critical Difference: Controlled vs. Non-Controlled Status

Here’s where things get interesting from a telehealth perspective: Strattera and most other ADHD non-stimulants are not controlled substances. This distinction is crucial because it means they’re not subject to the Drug Enforcement Administration’s (DEA) strict prescribing rules that govern stimulant medications.

The DEA classifies stimulant ADHD medications (Adderall, Ritalin, Vyvanse) as Schedule II controlled substances due to their potential for abuse and dependence. Strattera, on the other hand, carries no DEA scheduling because it’s not habit-forming and has no street value. This non-controlled status creates significantly more flexibility for telehealth prescribing.

Who Benefits Most from Non-Stimulants?

Non-stimulant medications may be the right choice if you:

• Have a history of substance use disorders
• Experience intolerable side effects from stimulants (anxiety, insomnia, appetite loss)
• Have certain cardiovascular conditions that make stimulants risky
• Prefer a medication without abuse potential
• Need 24-hour symptom coverage (Strattera provides consistent effects)
• Are concerned about stimulant medication being diverted or stolen

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules for ADHD Medications in 2025

Understanding federal regulations is the foundation for navigating ADHD telehealth care. The legal landscape has shifted dramatically since 2020, and staying current on these changes is essential.

The Ryan Haight Act: The Baseline Federal Law

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 established the federal framework for prescribing controlled substances via the internet. Under normal circumstances, this law requires an in-person medical evaluation before a practitioner can prescribe Schedule II–V controlled substances to a patient they’ve never met face-to-face.

Here’s the key point: The Ryan Haight Act applies only to controlled substances. Since Strattera and other non-stimulant ADHD medications aren’t controlled, they were never subject to this in-person requirement—even before the COVID-19 pandemic.

COVID-Era Telehealth Flexibilities: Where We Stand Now

When COVID-19 hit in March 2020, the DEA issued emergency waivers allowing healthcare providers to prescribe controlled substances (including ADHD stimulants) via telehealth without a prior in-person exam. This was game-changing for ADHD patients who suddenly had access to care from home.

As of December 2025, these flexibilities remain in effect but are temporary. The DEA’s ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities’ extends telehealth prescribing of Schedule II–V controlled substances through December 31, 2025. This means that right now, qualified providers can prescribe both stimulant and non-stimulant ADHD medications via telehealth appointments.

However, there’s uncertainty ahead. The DEA has proposed a ‘Special Registration’ framework that would create permanent telehealth pathways with additional safeguards, but this hasn’t been finalized. A fourth extension for 2026 is anticipated and currently under review, but if no new rule is issued, the Ryan Haight Act’s in-person requirements could resume for controlled substances on January 1, 2026.

What this means for non-stimulant medications: Regardless of what happens with stimulant prescribing rules, Strattera and other non-controlled ADHD medications can continue to be prescribed via telehealth because they’re exempt from these federal restrictions.

Provider Requirements

For a healthcare provider to legally prescribe ADHD medications through telehealth, they must:

• Hold an active medical license in your state
• Have a DEA registration (if prescribing controlled substances)
• Follow standard medical care practices and establish a legitimate provider-patient relationship
• Comply with state-specific telehealth regulations

At Klarity Health, we ensure all our providers meet these requirements and stay current on evolving regulations. Our platform connects you with licensed MDs and NPs who specialize in ADHD care and are credentialed in your specific state.

State-by-State Telehealth Rules: What You Need to Know

While federal law sets the baseline, state regulations can be more restrictive. Let’s break down the key variations you might encounter depending on where you live.

States with Minimal Telehealth Restrictions

California, Illinois, Pennsylvania: These states have embraced telehealth with relatively few barriers. In California, for example, telehealth appointments satisfy the state’s ‘good faith examination’ requirement for prescribing. There’s no mandatory in-person visit for non-controlled medications, and providers can establish care relationships entirely through secure video platforms.

California has been considering Assembly Bill 1503, which would further clarify that telehealth examinations equal prior exams for prescription purposes, though this legislation is still pending.

New Hampshire: Following significant reforms in August 2025, New Hampshire removed its prior in-person requirement through Senate Bill 252. Now, providers must conduct follow-up evaluations at least annually for controlled medication prescriptions, but these can be done via telehealth. For non-controlled medications like Strattera, there are no special requirements beyond standard care practices.

States with Periodic In-Person Requirements

Alabama: Alabama maintains one of the strictest telehealth policies in the nation. If you receive ongoing telehealth treatment for the same condition after four visits, you must have an in-person exam within 12 months. However, there’s an important exception: mental health services are exempt from this rule, which means ADHD psychiatric care may not require the annual in-person visit.

Additionally, Alabama requires that a licensed medical professional be physically present with the patient during initial controlled substance telehealth appointments (creating what some call the ‘Alabama loophole’). This doesn’t apply to non-controlled medications like Strattera, but it demonstrates the state’s cautious approach.

States with Controlled-Substance-Specific Rules

New York: In May 2025, New York implemented final rules requiring an initial in-person evaluation before prescribing any controlled substance via telemedicine. This reinstated Ryan Haight-style standards at the state level. However, this restriction only applies to controlled substances—Strattera can still be prescribed through telehealth without an in-person prerequisite.

Florida: Florida law prohibits telehealth prescribing of Schedule II medications (including stimulants) unless the medication is for treating a psychiatric disorder, or the patient is hospitalized, in hospice, or in a nursing facility. Since ADHD is classified as a psychiatric condition, this exception applies, making stimulant prescriptions via telehealth permissible. Non-stimulants like Strattera face no such restrictions.

Texas: Texas is generally telehealth-friendly for mental health services but has specific limitations on who can prescribe what. The state requires in-person visits for chronic pain management via telehealth but does not impose this requirement for ADHD treatment. However, Texas restricts Nurse Practitioners and Physician Assistants from prescribing Schedule II medications outside of hospital or hospice settings—a consideration if you’re seeking care from an NP.

Prescription Monitoring Program (PMP) Requirements

Many states require healthcare providers to check Prescription Monitoring Programs (databases tracking controlled substance prescriptions) before prescribing certain medications:

• Florida: Requires PMP checks before every controlled substance prescription
• California: Mandates checks at least every four months for ongoing controlled substance therapy
• New York: Requires PMP consultation each time a controlled substance is prescribed
• Georgia: Mandates checks at first prescription and then every 90 days

Since Strattera isn’t a controlled substance, these PMP requirements typically don’t apply legally. However, responsible providers often review patient medication histories regardless, as part of comprehensive care.

Who Can Prescribe ADHD Medications Through Telehealth?

Not all healthcare providers have the same prescribing authority, and understanding these differences can help you find the right telehealth service.

Physicians (MD/DO)

Licensed physicians—whether Medical Doctors (MDs) or Doctors of Osteopathic Medicine (DOs)—have full prescribing authority in all 50 states. If properly licensed in your state and registered with the DEA (for controlled substances), physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth according to current federal and state laws.

Nurse Practitioners (NPs)

Nurse Practitioner prescribing authority varies significantly by state:

Full Practice Authority States (including New York, Illinois, New Hampshire): NPs can practice independently and prescribe Schedule II–V medications without physician oversight after meeting certain experience requirements (typically 3,600–4,000 supervised hours). In these states, NPs can diagnose ADHD and prescribe both stimulants and non-stimulants via telehealth.

Restricted Practice States (including Texas, Georgia, Alabama): NPs must have collaborative agreements with physicians. Some states further restrict Schedule II prescribing:

• Georgia: NPs cannot prescribe Schedule II controlled substances at all, even with physician collaboration
• Texas: NPs can only prescribe Schedule II medications in hospital or hospice settings, not in typical outpatient care
• Alabama: NPs can prescribe Schedule II with special certification (LPSP permit) and collaboration

For Strattera specifically: Since it’s not a controlled substance, NPs in all states can prescribe it (assuming they have at least a collaborative practice agreement where required). This makes non-stimulants accessible through a broader range of providers.

Physician Assistants (PAs)

PAs generally practice under physician supervision and delegation agreements. Their controlled substance prescribing authority mirrors the restrictions placed on NPs in most states. For non-controlled ADHD medications, PAs across the country can prescribe with appropriate supervision.

Klarity’s Approach: At Klarity Health, we work with both physicians and nurse practitioners who are fully licensed and credentialed in their respective states. We match you with providers who have the appropriate authority to prescribe the medications you may need, ensuring compliance with your state’s specific regulations.

What to Expect from a Telehealth ADHD Evaluation

If you’re new to telehealth mental healthcare, understanding the evaluation process can ease anxiety and help you prepare.

The Comprehensive Initial Assessment

Legitimate telehealth ADHD services don’t simply hand out prescriptions based on a quick questionnaire. A proper evaluation follows the same diagnostic standards as in-person care, using DSM-5 criteria for ADHD diagnosis.

Your initial telehealth appointment will typically include:

Detailed Symptom Review: Your provider will ask about specific ADHD symptoms across different settings (work, school, home, relationships). They’ll want to know about both inattentive symptoms (difficulty focusing, forgetfulness, disorganization) and hyperactive/impulsive symptoms (restlessness, interrupting, difficulty waiting).

Developmental History: ADHD is a neurodevelopmental disorder that begins in childhood. Your provider will explore when symptoms first appeared and how they’ve affected you throughout your life. They may ask about school performance, childhood behavior reports, or even request old report cards.

Medical and Psychiatric History: Expect questions about other mental health conditions (anxiety, depression, bipolar disorder), substance use history, cardiovascular health, and current medications. This helps identify contraindications and ensures safe prescribing.

Functional Impact Assessment: How do symptoms affect your daily life? Your provider needs to understand the real-world impairment ADHD causes—at work, in relationships, or managing daily responsibilities.

Standardized Rating Scales: Many providers use validated tools like the Adult ADHD Self-Report Scale (ASRS) or Conners’ Adult ADHD Rating Scales to quantify symptom severity.

Collateral Information: For a thorough evaluation, providers may request information from family members or close contacts who can verify symptoms in different contexts.

Why Non-Stimulants Might Be Recommended

During your evaluation, your provider might suggest starting with a non-stimulant medication like Strattera for several reasons:

Lower Regulatory Complexity: Non-controlled status means easier refills, longer supplies (90 days vs. 30 days), and fewer restrictions—which can improve treatment adherence.

Better for Certain Profiles: If you have comorbid anxiety, a history of substance use, cardiovascular concerns, or difficulty with stimulant side effects, non-stimulants offer a safer alternative.

24-Hour Coverage: Unlike short-acting stimulants that wear off, Strattera provides consistent symptom management throughout the day and night.

Professional or Personal Preferences: Some patients prefer avoiding controlled substances for personal, professional, or insurance reasons.

Red Flags That May Disqualify You (Temporarily)

Telehealth providers screen carefully for patient safety. You may not be immediately eligible for ADHD medication via telehealth if you have:

• Active substance use disorders requiring specialized treatment
• Uncontrolled severe mental health conditions (acute psychosis, unstable bipolar disorder, active suicidal ideation)
• Certain cardiovascular conditions (for stimulants specifically)
• Narrow-angle glaucoma or recent MAOI use (contraindications for Strattera)
• Signs of ‘doctor shopping’ or medication-seeking behavior

This doesn’t mean you can’t receive ADHD care—it may mean you need additional in-person evaluation, stabilization of other conditions first, or coordination with specialists before starting medication via telehealth.

The Treatment Process: From Diagnosis to Ongoing Care

Once diagnosed, your telehealth ADHD treatment journey involves several phases.

Starting Strattera: What to Expect

If your provider prescribes Strattera, they’ll likely:

Start with a Lower Dose: Typical starting doses are 40 mg daily for adults, with gradual increases based on response and tolerability. This titration approach minimizes side effects.

Set Realistic Expectations: Unlike stimulants that work within hours, Strattera requires patience. You may notice some improvement within 1–2 weeks, but full therapeutic benefits typically emerge after 4–6 weeks of consistent use.

Monitor for Side Effects: Common initial side effects include decreased appetite, nausea, dry mouth, dizziness, and fatigue. Most side effects diminish after the first few weeks. Your provider will want to hear about your experience at follow-up appointments.

Check Important Warnings: Strattera carries an FDA black box warning for increased suicidal thinking in children and adolescents. Your provider will discuss this risk and monitor mood changes. Strattera can also affect blood pressure and heart rate, requiring periodic monitoring.

Follow-Up Care and Medication Management

Regular Check-Ins: Expect follow-up appointments every 1–3 months initially, then potentially quarterly once stable. These visits assess symptom improvement, side effects, and overall functioning.

Dose Adjustments: Your provider may increase your Strattera dose gradually (up to the maximum of 100 mg daily for adults) if your initial response is inadequate. Telehealth makes these adjustments convenient—no need to take time off work for brief check-ins.

Combination Approaches: Many patients benefit from combining medication with behavioral strategies, coaching, or therapy. Klarity Health can connect you with both medication management and therapeutic support, creating a comprehensive treatment plan.

Prescription Refills: Since Strattera isn’t controlled, refills are straightforward. You can often get 90-day supplies, and prescriptions can include multiple refills (unlike Schedule II stimulants that require a new prescription monthly). Most telehealth platforms offer easy refill request systems.

Switching or Adding Medications

If Strattera alone doesn’t provide adequate symptom control, your provider has several options:

• Increase the dose (if side effects are tolerable)
• Add a stimulant medication for additional coverage (under current DEA rules)
• Switch to a different non-stimulant like Qelbree or guanfacine
• Incorporate adjunctive treatments targeting specific symptoms

Telehealth makes these adjustments accessible without the burden of repeated in-person appointments, though your provider may occasionally recommend in-person visits for complex medication changes or concerning symptoms.

Choosing a Reputable Telehealth ADHD Provider

The telehealth ADHD space has exploded in recent years—bringing both quality services and concerning ‘pill mills.’ Here’s how to identify legitimate care.

Warning Signs of Questionable Services

Red flags that should make you cautious:

• Guarantees of prescription before evaluation
• No live video requirement (text/phone only for initial visits)
• Minimal medical history or symptom assessment
• No discussion of non-medication treatments or alternatives
• Unwillingness to coordinate with your other healthcare providers
• Lack of clear information about provider credentials
• Prices that seem too good to be true
• Offering to ship medications directly (especially from overseas)

What Quality Telehealth ADHD Care Looks Like

Reputable services like Klarity Health demonstrate:

Licensed, Credentialed Providers: All clinicians should be licensed in your state with appropriate DEA registrations. Klarity makes provider credentials transparent—you’ll know exactly who you’re seeing and their qualifications.

Comprehensive Evaluations: Expect 30–60 minute initial appointments with thorough diagnostic assessments. Quality services don’t rush the diagnostic process.

Evidence-Based Practices: Providers should follow DSM-5 diagnostic criteria, discuss both medication and non-medication treatments, and explain the rationale for their recommendations.

Ongoing Monitoring: Legitimate services require regular follow-ups to assess treatment response and safety. You shouldn’t get a prescription and then have no contact with your provider for months.

Care Coordination: Good telehealth platforms encourage (and sometimes require) communication with your primary care doctor and coordinate care when you have multiple providers.

Transparent Pricing: You should know upfront what appointments and prescriptions cost. Klarity offers clear pricing for both insurance and cash-pay patients, so there are no surprises.

Patient Education: Quality providers take time to educate you about your condition, medication options (including risks and benefits), and what to expect from treatment.

The Recent Scrutiny and What It Means

In 2022–2023, several high-profile telehealth ADHD companies faced federal investigations for allegedly over-prescribing stimulants. Companies like Cerebral and Done came under DEA and Department of Justice scrutiny, with Cerebral ultimately stopping most controlled substance prescribing.

These investigations created a wake-up call for the industry. Legitimate telehealth providers responded by:

• Implementing more rigorous diagnostic protocols
• Requiring more thorough documentation
• Instituting regular drug screening for some patients on controlled substances
• Creating treatment agreements similar to pain management contracts
• Enhancing provider training on safe prescribing practices
• Improving coordination with pharmacies and other healthcare providers

For patients, this is actually good news: The increased oversight has weeded out bad actors while pushing quality providers to adopt best practices. When you work with an established, reputable service, you can trust that they’re taking compliance and patient safety seriously.

Insurance Coverage and Costs

Understanding the financial aspects of telehealth ADHD care helps you make informed decisions.

Insurance Coverage for Telehealth

Most insurance plans now cover telehealth appointments at parity with in-person visits, thanks to pandemic-era policy changes that have largely become permanent. However, coverage details vary:

What’s Typically Covered:

• Initial diagnostic evaluation
• Follow-up medication management appointments
• Mental health therapy sessions (if offered alongside medication)

Potential Coverage Limitations:

• Some plans may require prior authorization for ADHD medications
• Out-of-network telehealth providers may have higher cost-sharing
• A few insurers still have restrictions on telehealth frequency or types of services

Klarity’s Approach: We accept many major insurance plans and verify coverage before your appointment. Our team handles the administrative work—submitting claims and navigating insurance requirements—so you can focus on your treatment.

Cash-Pay Options

For those without insurance or with high deductibles, cash-pay telehealth can be cost-effective:

Typical Cash-Pay Costs:

• Initial ADHD evaluation: $150–$300
• Follow-up appointments: $75–$150
• Strattera medication: $50–$150/month (generic atomoxetine is much less expensive than brand-name; prices vary by pharmacy)

Advantages of Cash-Pay:

• No insurance authorization delays
• No insurance records of mental health treatment
• Often faster appointment availability
• Transparent, predictable pricing

At Klarity Health, we offer both insurance and cash-pay options with upfront pricing transparency. You can compare costs and choose what works best for your situation.

Medication Costs

Strattera/Atomoxetine: Generic atomoxetine significantly reduced costs compared to brand-name Strattera. With manufacturer coupons, pharmacy discount programs, or apps like GoodRx, monthly costs for generic atomoxetine typically range from $30–$80.

90-Day Supplies: Since Strattera isn’t controlled, you can request 90-day supplies, which often reduce per-month costs and save you pharmacy trips.

Insurance Formularies: Most insurance plans cover generic atomoxetine, though some may require trying a stimulant first (step therapy). Your telehealth provider can work with your insurance to obtain necessary authorizations.

Practical Considerations for Telehealth ADHD Treatment

Beyond regulations and costs, several practical factors affect your telehealth experience.

Technology Requirements

Minimum Technical Needs:

• Smartphone, tablet, or computer with camera and microphone
• Stable internet connection
• Private space for confidential video appointments
• Updated browser or telehealth app (platform-specific)

Most telehealth platforms, including Klarity, have user-friendly apps or web portals. Technical support should be available if you encounter difficulties.

Privacy and Confidentiality

Your telehealth appointments are protected by HIPAA, the same privacy law that governs in-person care. Reputable platforms use encrypted video connections and secure health records systems.

Your Responsibilities:

• Choose a private location for appointments (not public spaces or open offices)
• Use headphones if others are nearby
• Ensure your device has updated security software
• Never share your login credentials

Pharmacy Coordination

Electronic Prescribing: Most telehealth providers send prescriptions electronically directly to your chosen pharmacy. This is standard practice and doesn’t indicate whether your visit was telehealth or in-person.

Potential Pharmacy Issues: In 2023, some pharmacies became more cautious about filling telehealth stimulant prescriptions following the media coverage of overprescribing concerns. However, this rarely affects Strattera prescriptions since it’s not controlled. Using the same pharmacy consistently and choosing reputable telehealth services minimizes any potential friction.

Mail-Order Pharmacies: Since Strattera can be prescribed in 90-day supplies, mail-order pharmacies through your insurance can offer convenience and cost savings.

Travel and Multi-State Considerations

Provider Licensing: Healthcare providers must be licensed in the state where you’re physically located during your appointment. If you travel frequently or plan to move, discuss this with your provider.

Prescription Transfers: If you move to a new state, you’ll need a provider licensed in that state. Most telehealth platforms can help facilitate transitions or recommend local providers.

Klarity’s Flexibility: We operate in multiple states and can often help you transition your care if you relocate to a state where we have licensed providers.

Common Questions and Misconceptions

‘Online ADHD prescriptions are automatic’

Reality: Legitimate telehealth ADHD evaluations are comprehensive and follow the same diagnostic standards as in-person visits. Providers must conduct thorough assessments, and there’s no guarantee you’ll receive medication. In fact, a quality provider might determine you don’t have ADHD or that a different treatment approach is more appropriate.

‘Non-stimulants don’t work as well as stimulants’

Reality: While stimulants are often first-line treatments, non-stimulants like Strattera can be equally or more effective for certain patients. Response varies individually. Strattera offers several advantages: no abuse potential, smooth 24-hour coverage, and benefits for comorbid anxiety. About 60–70% of patients respond well to Strattera when given adequate time at therapeutic doses.

‘Telehealth doctors can’t prescribe controlled medications’

Reality: Under current federal rules (through at least December 31, 2025), properly registered telehealth providers can prescribe controlled ADHD medications, including stimulants. Thousands of patients successfully receive controlled medications via telehealth. The key is ensuring your provider is licensed, DEA-registered, and following all applicable regulations.

For non-controlled medications like Strattera, there has never been a federal restriction on telehealth prescribing—even before COVID-19.

‘Local pharmacies won’t fill telehealth prescriptions’

Reality: Most pharmacies routinely fill legitimate telehealth prescriptions. Electronic prescriptions don’t indicate whether your visit was virtual or in-person. While some pharmacies became more cautious about certain telehealth stimulant prescriptions in 2023, this rarely affects non-controlled medications like Strattera.

Using established telehealth platforms and maintaining a relationship with one pharmacy helps ensure smooth prescription fills.

The Future of ADHD Telehealth: What’s Ahead for 2026 and Beyond

The regulatory landscape for telehealth ADHD treatment continues to evolve. Here’s what patients should watch for:

DEA Rulemaking

The DEA’s temporary telehealth flexibilities for controlled substances expire December 31, 2025. Several scenarios are possible:

Fourth Extension: Most likely, the DEA will issue another temporary extension for 2026 while continuing to work on permanent rules. This would maintain the status quo.

New Permanent Framework: The DEA has proposed a ‘Special Registration’ system that would allow telehealth prescribing of controlled substances under specific conditions (enhanced patient verification, follow-up requirements, prescriber accountability). If finalized, this could create permanent pathways for telehealth stimulant prescribing.

Return to Ryan Haight Requirements: If no extension or new rule is issued, providers would need to conduct an in-person exam before prescribing controlled substances via telehealth. This would significantly disrupt care for patients currently receiving stimulant medications through telehealth.

What this means for Strattera patients: Regardless of DEA decisions about controlled substances, non-stimulant prescribing via telehealth will continue unaffected. Strattera and other non-controlled ADHD medications remain outside the scope of these federal restrictions.

State-Level Trends

Expansion of Access: More states are moving toward permanent telehealth parity and reducing unnecessary barriers. New Hampshire’s 2025 reforms exemplify this trend.

Enhanced Safeguards: Simultaneously, states are strengthening prescription monitoring programs, requiring e-prescribing, and enhancing oversight—balancing access with patient safety.

APRN Authority: Several states are considering expanding Nurse Practitioner prescribing authority. Texas has discussed allowing NPs to prescribe Schedule II medications in broader settings, though as of late 2025, these expansions haven’t passed.

Industry Best Practices

Expect continued evolution in telehealth ADHD care quality:

Integrated Care Models: More platforms are combining medication management with therapy, coaching, and wraparound services for comprehensive ADHD treatment.

Technology Integration: Enhanced digital tools for symptom tracking, medication reminders, and patient-provider communication are improving treatment outcomes.

Research and Outcomes: Growing data on telehealth ADHD treatment effectiveness will help refine protocols and demonstrate that virtual care can match in-person quality when done properly.

How Klarity Health Supports Your ADHD Journey

At Klarity Health, we’ve designed our telehealth platform specifically to address the challenges ADHD patients face in accessing quality, convenient, and affordable care.

Our Approach to ADHD Care

Licensed Providers in Your State: We connect you with board-certified physicians and nurse practitioners who are fully licensed and credentialed in your state. Our providers specialize in ADHD and stay current on evolving regulations.

Comprehensive Evaluations: We don’t cut corners on diagnosis. Your initial appointment includes a thorough assessment following DSM-5 criteria, with time to discuss your symptoms, history, and treatment goals.

Flexible Treatment Options: Our providers can prescribe both stimulant and non-stimulant ADHD medications when clinically appropriate. We discuss the full range of treatment options, including medications like Strattera, lifestyle strategies, and therapy referrals.

Transparent Pricing: We accept most major insurance plans and also offer clear cash-pay pricing. You’ll know your costs upfront with no surprise bills.

Convenient Scheduling: Book appointments that fit your schedule, including evenings and weekends. Most patients can get an initial appointment within days, not months.

Ongoing Support: We provide regular follow-up care, easy prescription refills, and responsive patient support. Your care doesn’t end when your appointment does.

Why Patients Choose Klarity

Provider Availability: Unlike traditional psychiatry, where waiting lists can stretch 3–6 months, Klarity offers rapid access to ADHD specialists.

Quality Standards: We maintain rigorous provider credentialing and clinical oversight to ensure evidence-based, ethical care that prioritizes your health over prescription volume.

Coordinated Care: We encourage communication with your other healthcare providers and can integrate ADHD treatment into your broader health management.

Both Insurance and Cash Pay: Whether you have insurance or prefer to pay out-of-pocket, we offer accessible options.

Taking the First Step

If you’re struggling with ADHD symptoms and wondering whether telehealth treatment might be right for you, here’s how to get started:

Prepare for Your Evaluation

Gather Information:

• Write down your symptoms and when they occur
• Note how ADHD impacts your work, relationships, and daily functioning
• List current and past medications
• Document any substance use history
• Collect medical records if available (especially previous ADHD diagnoses or treatment)

Consider Your Goals: What do you hope to achieve with ADHD treatment? Better focus at work? Improved relationships? Organizational skills? Reduced anxiety? Clear goals help your provider tailor treatment.

Be Honest: Your provider needs complete, accurate information to help you safely and effectively. This isn’t a test you need to ‘pass’—it’s a clinical evaluation to understand your needs.

What Questions to Ask

During your telehealth appointment, don’t hesitate to ask:

• What are the diagnostic criteria you’re using?
• Why are you recommending this particular medication?
• What side effects should I watch for?
• How long until I should expect improvement?
• What happens if this medication doesn’t work well for me?
• How often will we have follow-up appointments?
• What should I do if I have concerns between appointments?
• How does your platform handle prescription refills?

Schedule Your Appointment with Klarity

Ready to explore whether telehealth ADHD treatment is right for you? Klarity Health makes it easy:

1. Visit our website and complete a brief intake form
2. Schedule your appointment at a time that works for you
3. Meet with your provider via secure video from the comfort of home
4. Receive personalized treatment recommendations based on a comprehensive evaluation
5. Get prescriptions sent directly to your preferred pharmacy if medication is appropriate
6. Access ongoing support with regular follow-ups and responsive care

ADHD doesn’t have to hold you back. With accessible, quality telehealth care, you can take control of your symptoms and thrive in work, relationships, and life.

Conclusion

The answer to ‘Can I get ADHD non-stimulant medication through telehealth?’ is a resounding yes in 2025. Non-stimulant medications like Strattera are not controlled substances, which means they’re not subject to the complex federal prescribing restrictions that govern stimulant medications. Properly licensed telehealth providers can evaluate you, diagnose ADHD, and prescribe non-stimulants through secure video appointments in virtually all 50 states.

While regulations continue to evolve—particularly around controlled stimulant medications—non-stimulant ADHD treatment via telehealth remains stable and accessible. State laws add some variation, with a few states requiring periodic in-person visits or having specific rules for controlled substances, but these rarely impact non-stimulant prescribing.

The key is choosing a reputable telehealth provider that prioritizes comprehensive evaluations, evidence-based treatment, and patient safety over simply dispensing prescriptions. Quality telehealth ADHD care should match in-person standards while offering the convenience and accessibility that modern patients need.

If you’re ready to explore ADHD treatment through a trusted telehealth platform, Klarity Health offers the expertise, convenience, and personalized care you deserve. Our licensed providers are here to help you understand your symptoms, explore treatment options, and develop a plan that works for your unique situation—all from the comfort of home.

References

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities’ – Federal Register (Nov 2024). Fierce Healthcare. [https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final](https://www.fiercehealthcare.com/regulatory/dea-finalizes

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment